Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.71 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.63 |
| ▸ | PPARA | Q07869 | 2/20 | 0.63 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14463137 | 0.89 | PPARG (0.57) | PPARGNR1H4PPARANLRP3HDAC3 | |
| SCHEMBL4955789 | 0.85 | PPARG (0.73) | PPARGNR1H4PPARAL3MBTL1HPGD | |
| SCHEMBL13593280 | 0.85 | NLRP3 (0.69) | PPARGNR1H4NLRP3HDAC3HDAC1 | |
| SCHEMBL4954794 | 0.84 | PPARG (0.71) | PPARGNR1H4PPARAHDAC3HDAC1 | |
| SCHEMBL4954313 | 0.82 | PPARG (0.67) | PPARGNR1H4PPARAHPGDHTT | |
| SCHEMBL4954366 | 0.81 | PPARG (0.66) | PPARGNR1H4PPARAHPGDHTT | |
| SCHEMBL4955565 | 0.81 | PPARG (0.66) | PPARGNR1H4PPARAHPGDHTT | |
| SCHEMBL4954952 | 0.80 | PPARG (0.65) | PPARGNR1H4PPARAL3MBTL1 | |
| SCHEMBL31661816 | 0.80 | SMN1; SMN2 (0.53) | PPARGNLRP3TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL15038314 | 0.80 | NLRP3 (0.79) | NLRP3HDAC3HDAC1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462735-B2 | Amino acid diamides in non α position which are useful as adjuvants for administration of biological active agents | LABORATORIOS FARMACEUTICOS ROVI, S.A. (ES) | 2008-12-09 | — | — | US | disclosed |
| US-7462735-B2 | Amino acid diamides in non α position which are useful as adjuvants for administration of biological active agents | LABORATORIOS FARMACEUTICOS ROVI, S.A. (ES) | 2008-12-09 | — | — | US | disclosed |
| US-7462735-B2 | Amino acid diamides in non α position which are useful as adjuvants for administration of biological active agents | LABORATORIOS FARMACEUTICOS ROVI, S.A. (ES) | 2008-12-09 | — | — | US | disclosed |
| US-20070191302-A1 | AMINO ACID DIAMIDES IN NON ALPHA POSITION WHICH ARE USEFUL AS ADJUVANTS FOR ADMINISTRATION OF BIOLOGICAL ACTIVE AGENTS | LABORATORIOS FARMACEUTICOS ROVI S.A. (ES) | 2007-08-16 | — | — | US | disclosed |
| US-20070191302-A1 | AMINO ACID DIAMIDES IN NON ALPHA POSITION WHICH ARE USEFUL AS ADJUVANTS FOR ADMINISTRATION OF BIOLOGICAL ACTIVE AGENTS | LABORATORIOS FARMACEUTICOS ROVI S.A. (ES) | 2007-08-16 | — | — | US | disclosed |
| US-20070191302-A1 | AMINO ACID DIAMIDES IN NON ALPHA POSITION WHICH ARE USEFUL AS ADJUVANTS FOR ADMINISTRATION OF BIOLOGICAL ACTIVE AGENTS | LABORATORIOS FARMACEUTICOS ROVI S.A. (ES) | 2007-08-16 | — | — | US | disclosed |
| EP-1652836-B1 | AMINO ACID DIAMIDES IN NON ALPHA POSITION USEFUL AS ADJUVANTS FOR THE ADMINISTRATION OF ACTIVE BIOLOGICAL AGENTS | ROVI LAB FARMACEUT SA (ES) | 2007-07-18 | — | — | EP | disclosed |
| EP-1652836-A1 | AMINO ACID DIAMIDES IN NON ALPHA POSITION USEFUL AS ADJUVANTS FOR THE ADMINISTRATION OF ACTIVE BIOLOGICAL AGENTS | LABORATORIOS FARMACEUTICOS ROVI, S.A. (ES) | 2006-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191302-A1 | AMINO ACID DIAMIDES IN NON ALPHA POSITION WHICH ARE USEFUL AS ADJUVANTS FOR ADMINISTRATION OF BIOLOGICAL ACTIVE AGENTS | NOS1, NOS3, ARG1 | PPARG 3783/4885NR1H4 2582/4885PPARA 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.